10-Q: Arrowhead Pharma Q2 2026: Revenue Dip, Pipeline Advances

Arrowhead Pharmaceuticals reports a significant revenue decrease in its second fiscal quarter of 2026 compared to the prior year, primarily due to lower Sarepta collaboration revenue, while advancing its pipeline with new clinical trial initiations and regulatory milestones.

Summary

• Arrowhead Pharmaceuticals reported a net loss of $132.7 million for the three months ended March 31, 2026, compared to a net income of $370.4 million in the same period last year. Diluted loss per share was $0.93.
• Total revenue for the quarter decreased to $73.7 million from $542.7 million in the prior year's quarter, largely due to reduced revenue from the Sarepta collaboration.
• Research and development expenses increased by 30% to $173.3 million, driven by pipeline progression and higher outsourced clinical trial costs.
• Selling, general, and administrative expenses rose by 47% to $41.7 million, reflecting increased commercialization costs for REDEMPLO and higher headcount.
• The company ended the quarter with $188.5 million in cash, cash equivalents, and restricted cash, and $1.6 billion in available-for-sale securities, expecting sufficient liquidity for at least the next twelve months.
• Key developments include the initiation of a Phase 1/2a trial for ARO-DIMER-PA, FDA Breakthrough Therapy designation for plozasiran, and approvals for REDEMPLO in China and Canada.
• Subsequent to the quarter, Arrowhead entered into a licensing agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, receiving a $25 million upfront payment and potential milestone payments.
• The company also announced a positive CHMP opinion for REDEMPLO in Europe and TGA approval in Australia.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant decrease in revenue and the shift from net income to net loss, despite positive pipeline developments and substantial capital raises.

Positives

• REDEMPLO (plozasiran) received regulatory approvals in China and Canada, and a positive CHMP opinion in Europe, with TGA approval in Australia.
• FDA granted Breakthrough Therapy designation to investigational plozasiran for severe hypertriglyceridemia.
• Initiated Phase 1/2a clinical trials for ARO-DIMER-PA (targeting two genes simultaneously), ARO-INHBE (in combination with tirzepatide showing enhanced weight loss), ARO-ALK7 (first RNAi-therapeutic showing adipocyte gene target silencing), and ARO-MAPT (for tauopathies).
• Completed upsized offerings of convertible senior notes, common stock, and pre-funded warrants, raising $930.0 million in gross proceeds.
• Received a $200.0 million milestone payment from Sarepta Therapeutics and a $50.0 million annual fee installment.
• Entered into a significant licensing agreement with Novartis, receiving a $200.0 million upfront payment and eligible for up to $2.0 billion in milestones plus royalties.
• Entered into a licensing agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, receiving a $25 million upfront payment and eligible for up to $975 million in milestones plus royalties.

Negatives

• Revenue for the three months ended March 31, 2026, decreased by $469.0 million to $73.7 million compared to $542.7 million in the same period of 2025, primarily due to lower Sarepta revenue.
• Net loss attributable to Arrowhead Pharmaceuticals, Inc. was $132.7 million for the three months ended March 31, 2026, compared to a net income of $370.4 million in the same period of 2025.
• Diluted loss per share was $0.93 for the three months ended March 31, 2026, compared to diluted earnings per share of $2.75 in the same period of 2025.
• Research and development expenses increased by 30% to $173.3 million, and selling, general, and administrative expenses increased by 47% to $41.7 million, reflecting ongoing pipeline development and commercialization efforts.

Risks

• The company faces risks related to the initiation, timing, progress, and results of its preclinical studies and clinical trials.
• There is uncertainty regarding the potential benefits of partnership, licensing, and collaboration arrangements.
• Future milestone, royalty, or other payments from or to third parties are subject to various conditions and may not be realized.
• The company's ability to generate future revenues and achieve profitability depends on the successful development and commercialization of its product candidates.
• The company is subject to ongoing litigation, including a patent infringement lawsuit filed by Ionis Pharmaceuticals.
• The company's operations and financial condition could be materially impacted by the ongoing development of its pipeline, including the need for significant future cash expenditures.
• The company's ability to maintain sufficient liquidity to fund operations through at least the next twelve months is dependent on various factors, including the successful execution of its business plan.

Future Outlook

The company expects to have sufficient liquidity to fund its operations through at least the next twelve months. The company continues to develop other clinical candidates for future clinical trials and anticipates increased candidate costs as they progress through development.

Management Comments

• The company believes that TRiM™ enabled therapeutics offer several potential advantages over prior generations and competing technologies, including simplified manufacturing, reduced costs, multiple routes of administration, the ability to target multiple tissue types, and the potential for improved safety.
• The company operates as a single segment, with the CEO managing and allocating resources on a consolidated basis.
• The company's cash, cash equivalents, and restricted cash, along with available-for-sale securities, are expected to provide sufficient liquidity for at least the next twelve months.
• The company expects to have sufficient liquidity to fund its operations through at least the next twelve months from the date of the issuance of these unaudited consolidated financial statements.

Industry Context

StockSavvy.ai notes that Arrowhead Pharmaceuticals' Q2 2026 results reflect the dynamic nature of the biopharmaceutical industry, characterized by significant R&D investments, reliance on strategic partnerships, and the long, complex path to commercialization. The revenue dip, while notable, is common when large upfront payments or milestone achievements from prior periods do not recur. The company's focus on RNAi therapeutics and its proprietary TRiM™ platform positions it within a key area of innovation, aiming to address unmet needs in genetic diseases. The substantial cash and securities balance provides a buffer for continued pipeline development and potential future commercialization efforts.

Comparison to Industry Standards

• Arrowhead's R&D spending as a percentage of revenue (approximately 235% for the quarter) is high, which is typical for clinical-stage biopharmaceutical companies investing heavily in pipeline development, compared to established pharmaceutical giants where R&D as a percentage of revenue is generally lower.
• The company's revenue concentration with key partners like Sarepta, Novartis, and Sanofi is a common strategy in the industry to de-risk development and access external expertise and capital. However, this also leads to significant revenue fluctuations based on milestone achievements and collaboration terms, as seen with the decrease in Sarepta revenue.
• The significant increase in SG&A expenses, particularly related to commercialization, aligns with industry trends for companies nearing or entering the commercial phase for approved products like REDEMPLO.
• The company's substantial investment in available-for-sale securities ($1.6 billion) is a prudent approach to managing significant cash reserves, common among well-funded biotechs to preserve capital while earning modest returns, contrasting with companies that might deploy more capital into immediate operational expansion or acquisitions.

Legal Proceedings

• On September 10, 2025, the Company filed a Complaint for Declaratory Judgment against Ionis Pharmaceuticals, Inc. to declare United States Patent No. 9,593,333 invalid and not infringed by the Company's planned commercialization of investigational plozasiran.
• On December 23, 2025, the court granted Ionis' motion to dismiss the Delaware DJ action.
• On September 11, 2025, Ionis filed a Complaint for Patent Infringement against the Company alleging patent infringement of the 333 patent by the Company's planned commercialization of investigational plozasiran and seeking damages. The Company disputes the allegations and intends to vigorously defend itself.

Stakeholder Impact

• Shareholders may experience volatility due to the reported net loss and revenue decrease, although the substantial capital raises and pipeline advancements offer potential for future growth.
• Employees may be impacted by increased R&D and SG&A expenses, reflecting continued investment in pipeline and commercialization efforts, and potential future growth opportunities.
• Partners and collaborators (Sarepta, Novartis, Sanofi, GSK, Amgen, Takeda, Madrigal) will continue to work with Arrowhead on various programs, with revenue streams from these collaborations being critical to Arrowhead's financial performance.
• Creditors and debt holders are impacted by the company's financial performance and its ability to service its debt obligations, including the significant convertible notes and credit facility.

Next Steps

• The European Commission is expected to issue a decision on REDEMPLO's Marketing Authorization in the second calendar quarter of 2026.
• The company expects to have sufficient liquidity to fund its operations through at least the next twelve months.
• The company will continue to advance its pipeline of drug candidates through clinical trials.
• The company will continue to prepare for the manufacture of commercial material at the Verona facility.
• The company will continue to engage third-party contract research organizations (CROs) to manage clinical trials.

Key Dates

Recommendation

While Arrowhead Pharmaceuticals has a strong pipeline with promising developments and has secured significant funding, the substantial decrease in revenue and shift to a net loss in the current reporting period warrant a cautious approach. The company's future success hinges on the continued progression of its clinical trials and the commercialization of its products, which carry inherent risks. The current financial performance, while offset by strong future potential, suggests a 'hold' recommendation until further clarity on revenue generation and profitability emerges.

Keywords

Arrowhead Pharmaceuticals, SEC Filing, 10-Q, RNAi Therapeutics, REDEMPLO, plozasiran, Clinical Trials, Drug Development, Biotechnology, Pharmaceuticals, Sarepta Therapeutics, Novartis, Sanofi, Madrigal Pharmaceuticals, ARO-DIMER-PA, ARO-PNPLA3